The genetic landscape of histologically transformed marginal zone lymphomas.
TBL1XR1 mutations
de novo diffuse large B-cell lymphoma
histologic transformation
marginal zone lymphomas
non-germinal center B-cell subtype
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 Apr 2024
15 Apr 2024
Historique:
revised:
24
08
2023
received:
24
04
2023
accepted:
11
09
2023
pubmed:
9
11
2023
medline:
9
11
2023
entrez:
9
11
2023
Statut:
ppublish
Résumé
Marginal zone lymphomas (MZLs) comprise a diverse group of indolent lymphoproliferative disorders; however, some patients develop histologic transformation (HT) with rapid progression to aggressive lymphoma. Forty-three MZLs with HT (HT-MZLs), 535 MZLs, and 174 de novo diffuse large B-cell lymphomas (DLBCLs) without rearrangements of MYC, BCL2, and BCL6 were collected. Among these, 22 HT-MZLs, 39 MZLs, and 174 DLBCLs were subjected to 148-gene targeted exome sequencing. The clinicopathologic features of patients who had HT-MZL and their genetic alterations were compared with those of patients who had MZLs and DLBCLs. All 43 HT-MZLs corresponded to DLBCLs. No HT-MZLs harbored BCL2 and MYC and/or BCL6 rearrangements. Bone marrow involvement and higher levels of lactate dehydrogenase were significantly more common in HT-MZLs than in MZLs. Furthermore, upregulated BCL6, MUM1, C-MYC, and Ki-67 expression was observed more frequently in HT-MZLs than in MZLs. TBL1XR1 was the most frequently altered gene (63.6%) in HT-MZLs, followed by CCND3 (31.8%), CARD11, ID3, and TP53 (22.7%). A trend toward worse progression-free survival in patients with TBL1XR1 mutations was observed. Compared with MZLs and non-germinal center B-cell (GCB) type DLBCLs, significantly higher frequencies of TBL1XR1 and ID3 mutations were identified in HT-MZLs. PIM1 mutations frequently occurred in DLBCLs and were significantly associated with TBL1XR1 mutations but were mutated less in HT-MZLs that had TBL1XR1 mutations. The current findings reveal the clinicopathologic and genetic features of HT-MZLs, suggesting that these tumors might constitute a group distinct from MZL and de novo non-GCB type DLBCL. TBL1XR1 mutations may be considered a predictor of HT in MZL.
Sections du résumé
BACKGROUND
BACKGROUND
Marginal zone lymphomas (MZLs) comprise a diverse group of indolent lymphoproliferative disorders; however, some patients develop histologic transformation (HT) with rapid progression to aggressive lymphoma.
METHODS
METHODS
Forty-three MZLs with HT (HT-MZLs), 535 MZLs, and 174 de novo diffuse large B-cell lymphomas (DLBCLs) without rearrangements of MYC, BCL2, and BCL6 were collected. Among these, 22 HT-MZLs, 39 MZLs, and 174 DLBCLs were subjected to 148-gene targeted exome sequencing. The clinicopathologic features of patients who had HT-MZL and their genetic alterations were compared with those of patients who had MZLs and DLBCLs.
RESULTS
RESULTS
All 43 HT-MZLs corresponded to DLBCLs. No HT-MZLs harbored BCL2 and MYC and/or BCL6 rearrangements. Bone marrow involvement and higher levels of lactate dehydrogenase were significantly more common in HT-MZLs than in MZLs. Furthermore, upregulated BCL6, MUM1, C-MYC, and Ki-67 expression was observed more frequently in HT-MZLs than in MZLs. TBL1XR1 was the most frequently altered gene (63.6%) in HT-MZLs, followed by CCND3 (31.8%), CARD11, ID3, and TP53 (22.7%). A trend toward worse progression-free survival in patients with TBL1XR1 mutations was observed. Compared with MZLs and non-germinal center B-cell (GCB) type DLBCLs, significantly higher frequencies of TBL1XR1 and ID3 mutations were identified in HT-MZLs. PIM1 mutations frequently occurred in DLBCLs and were significantly associated with TBL1XR1 mutations but were mutated less in HT-MZLs that had TBL1XR1 mutations.
CONCLUSIONS
CONCLUSIONS
The current findings reveal the clinicopathologic and genetic features of HT-MZLs, suggesting that these tumors might constitute a group distinct from MZL and de novo non-GCB type DLBCL. TBL1XR1 mutations may be considered a predictor of HT in MZL.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1246-1256Subventions
Organisme : National Natural Science Foundation of China
ID : 82070207
Organisme : Science and Technology Commission of Shanghai Municipality
ID : 19441904900
Organisme : Science and Technology Commission of Shanghai Municipality
ID : 21ZR1440100
Informations de copyright
© 2023 American Cancer Society.
Références
Rossi D, Bertoni F, Zucca E. Marginal-zone lymphomas. N Engl J Med. 2022;386(6):568-581. doi:10.1056/nejmra2102568
Casulo C, Friedberg J. Transformation of marginal zone lymphoma (and association with other lymphomas). Best Pract Res Clin Haematol. 2017;30(1-2):131-138. doi:10.1016/j.beha.2016.08.029
Conconi A, Franceschetti S, Aprile von Hohenstaufen K, et al. Histologic transformation in marginal zone lymphomas. Ann Oncol. 2015;26(11):2329-2335. doi:10.1093/annonc/mdv368
Alderuccio JP, Zhao W, Desai A, et al. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol. 2019;94(5):585-596. doi:10.1002/ajh.25446
Meyer AH, Stroux A, Lerch K, et al. Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol. 2014;25(1):210-215. doi:10.1093/annonc/mdt507
Camacho Castaneda FI, Dotor A, Manso R, et al. Epstein-Barr virus-associated large B-cell lymphoma transformation in marginal zone B-cell lymphoma: a series of four cases. Histopathology. 2020;77(1):112-122. doi:10.1111/his.14101
Flossbach L, Antoneag E, Buck M, et al. BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int J Cancer. 2011;129(1):70-77. doi:10.1002/ijc.25663
Sagaert X, de Paepe P, Libbrecht L, et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(16):2490-2497. doi:10.1200/jco.2006.05.6150
Arribas AJ, Rinaldi A, Mensah AA, et al. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood. 2015;125(12):1922-1931. doi:10.1182/blood-2014-08-596247
Qian L, Soderquist C, Schrank-Hacker A, et al. Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma. Am J Hematol. 2020;95(3):238-244. doi:10.1002/ajh.25694
Kern JB, Duff DJ, Odem JL, et al. A novel del(20q) in aggressive nodal marginal zone lymphoma. Case Rep Pathol. 2013;2013:784176. doi:10.1155/2013/784176
Hatem J, Schrank-Hacker AM, Watt CD, et al. Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report. Diagn Pathol. 2016;11(1):137. doi:10.1186/s13000-016-0588-x
Deutsch AJ, Steinbauer E, Hofmann NA, et al. Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma. Mod Pathol. 2013;26(2):182-194. doi:10.1038/modpathol.2012.134
Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690. doi:10.1038/s41591-018-0016-8
Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551-568.e14. doi:10.1016/j.ccell.2020.03.015
Fan Y, Binshen O, Zhang Z, et al. De novo CD5-positive diffuse large B-cell lymphoma: a genomic profiling study and prognostic analysis of 46 patients. Ann Diagn Pathol. 2022;58:151886. doi:10.1016/j.anndiagpath.2021.151886
Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17-29. doi:10.1016/j.annonc.2019.10.010
Staiger AM, Ziepert M, Horn H, et al. Clinical impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017;35(22):2515-2526. doi:10.1200/jco.2016.70.3660
Huo YJ, Xu PP, Fu D, et al. Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication. Blood Cancer J. 2022;12(3):48. doi:10.1038/s41408-022-00644-2
Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006;8(2):141-151. doi:10.2353/jmoldx.2006.050083
Geyer FC, Li A, Papanastasiou AD, et al. Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nat Commun. 2018;9(1):1816. doi:10.1038/s41467-018-04128-5
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-1760. doi:10.1093/bioinformatics/btp324
Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-2079. doi:10.1093/bioinformatics/btp352
McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303. doi:10.1101/gr.107524.110
Shen R, Fu D, Dong L, et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):145. doi:10.1038/s41392-023-01358-y
1000 Genomes Project Consortium; Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68-74. doi:10.1038/nature15393
Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308-311. doi:10.1093/nar/29.1.308
van Dongen JJM, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317. doi:10.1038/sj.leu.2403202
Venturutti L, Teater M, Zhai A, et al. TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate. Cell. 2020;182(2):297-316.e27. doi:10.1016/j.cell.2020.05.049
Jung H, Yoo HY, Lee SH, et al. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP. Oncotarget. 2017;8(10):17038-17049. doi:10.18632/oncotarget.14928
Moody S, Thompson JS, Chuang SS, et al. Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites. Haematologica. 2018;103(8):1329-1336. doi:10.3324/haematol.2018.191601
Craig VJ, Cogliatti SB, Imig J, et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011;117(23):6227-6236. doi:10.1182/blood-2010-10-312231
Maeshima AM, Taniguchi H, Toyoda K, et al. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol. 2016;174(6):923-931. doi:10.1111/bjh.14153
Huang W, Guo L, Liu H, Zheng B, Ying J, Lv N. C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas. Int J Clin Exp Pathol. 2014;7:5634-5644.
Vela V, Juskevicius D, Dirnhofer S, Menter T, Tzankov A. Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin. Virchows Arch. 2022;480(2):403-413. doi:10.1007/s00428-021-03186-3
Hyeon J, Lee B, Shin SH, et al. Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. Mod Pathol. 2018;31(9):1418-1428. doi:10.1038/s41379-018-0064-0
Cascione L, Rinaldi A, Bruscaggin A, et al. Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. Haematologica. 2019;104(12):e558-e561. doi:10.3324/haematol.2018.214957
Ganapathi KA, Jobanputra V, Iwamoto F, et al. The genetic landscape of dural marginal zone lymphomas. Oncotarget. 2016;7(28):43052-43061. doi:10.18632/oncotarget.9678
Johansson P, Klein-Hitpass L, Budeus B, et al. Identifying genetic lesions in ocular adnexal extranodal marginal zone lymphomas of the MALT subtype by whole genome, whole exome and targeted sequencing. Cancers (Basel). 2020;12(4):986. doi:10.3390/cancers12040986
Vela V, Juskevicius D, Gerlach MM, et al. High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas. Hematol Oncol. 2020;38(3):284-292. doi:10.1002/hon.2718
Kiesewetter B, Lamm W, Dolak W, et al. Transformed mucosa-associated lymphoid tissue lymphomas: a single institution retrospective study including polymerase chain reaction-based clonality analysis. Br J Haematol. 2019;186(3):448-459. doi:10.1111/bjh.15953
Liu YX, Yoshino T, Ohara N, et al. Loss of expression of alpha4beta7 integrin and L-selectin is associated with high-grade progression of low-grade MALT lymphoma. Mod Pathol. 2001;14(8):798-805. doi:10.1038/modpathol.3880393